Autor según el artículo: Becerra-Tomas, Nerea; Ruiz-Canela, Miguel; Hernandez-Alonso, Pablo; Bullo, Monica; Li, Jun; Guasch-Ferre, Marta; Toledo, Estefania; Clish, Clary B.; Estruch, Ramon; Ros, Emilio; Fito, Montserrat; Lee, Chih-Hao; Pierce, Kerry; Aros, Fernando; Serra-Majem, Lluis; Liang, Liming; Razquin, Cristina; Gomez-Gracia, Enrique; Martinez-Gonzalez, Miguel A.; Hu, Frank B.; Corella, Dolores; Salas-Salvado, Jordi;

Departamento: Bioquímica i Biotecnologia

e-ISSN: 2218-1989

Autor/es de la URV: Becerra Tomás, Nerea / Bulló Bonet, Mònica / Salas Salvadó, Jorge

Palabras clave: Uric-acid Predimed study Heart failure Glycolysis Glucose Biomarkers Atrial fibrillation

Resumen: The increased prevalence of atrial fibrillation (AF) and heart failure (HF) highlights the need to better understand the mechanisms underlying these cardiovascular diseases (CVDs). In the present study, we aimed to evaluate the association between glycolysis-related metabolites and the risk of AF and HF in a Mediterranean population at high risk of CVD. We used two case-control studies nested within the PREDIMED trial. A total of 512 incident AF cases matched to 734 controls, and 334 incident HF cases matched to 508 controls, were included. Plasma metabolites were quantified by using hydrophilic interaction liquid chromatography coupled with high-resolution negative ion mode MS detection. Conditional logistic regression analyses were performed. The results showed no association between baseline plasma glycolysis intermediates and other related metabolites with AF. Only phosphoglycerate was associated with a higher risk of HF (OR (for 1 SD increase): 1.28; 95% CI: 1.06, 1.53). The present findings do not support a role of the glycolysis pathway in the pathogenesis of AF. However, the increased risk of HF associated with phosphoglycerate requires further studies.

Áreas temáticas: Molecular biology Medicina ii Farmacia Endocrinology, diabetes and metabolism Ciências biológicas ii Ciências biológicas i Biotecnología Biochemistry & molecular biology Biochemistry

Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/

Direcció de correo del autor: nerea.becerra@urv.cat jordi.salas@urv.cat monica.bullo@urv.cat

Identificador del autor: 0000-0002-4429-6507 0000-0003-2700-7459 0000-0002-0218-7046

Fecha de alta del registro: 2023-09-02

Volumen de revista: 11

Versión del articulo depositado: info:eu-repo/semantics/publishedVersion

Enlace a la fuente original: https://www.mdpi.com/2218-1989/11/5/306

URL Documento de licencia: http://repositori.urv.cat/ca/proteccio-de-dades/

Referencia al articulo segun fuente origial: Metabolites. 11 (5):

Referencia de l'ítem segons les normes APA: Becerra-Tomas, Nerea; Ruiz-Canela, Miguel; Hernandez-Alonso, Pablo; Bullo, Monica; Li, Jun; Guasch-Ferre, Marta; Toledo, Estefania; Clish, Clary B.; E (2021). Glycolysis Metabolites and Risk of Atrial Fibrillation and Heart Failure in the PREDIMED Trial. Metabolites, 11(5), -. DOI: 10.3390/metabo11050306

DOI del artículo: 10.3390/metabo11050306

Entidad: Universitat Rovira i Virgili

Año de publicación de la revista: 2021

Tipo de publicación: Journal Publications